Cabergoline Drug Asset Due Diligence Report 2026

This Cabergoline Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

119

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Cabergoline can convert its Small molecule drug profile and D2 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cabergoline (query alias: cabergoline)
Modality / target	Small molecule drug; D2 receptor; D2 receptor agonists
Highest global status	Approved
Originator	Pfizer Inc.
Active developers	Pfizer Inc., Pfizer Japan, Inc., Strides Pharma Global Pte Ltd.

The MCP disease footprint includes Lactation Disorders, Parkinson Disease, Hyperprolactinemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07603466	Phase 4	Enrolling by invitation	50	Changes in serum cortisol
NCT07463235	Phase 3	Recruiting	70	Remission
NCT07492160	Phase 2	Recruiting	348	Proportion of Participants With Breast Symptoms 4 Days After Abortion or Pregnancy Loss

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss

Phase 2; n=138; evaluation: Positive. Reported fields: Breast symptoms(day 4) = 88.2 % ; Breast symptoms(day 4) = 50.0 %

Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial

Phase 2; n=69; evaluation: not stated. Reported fields: Number of Participants Reporting Breast Pain = 30 Participants ; -; Number of Participants Reporting Breast Pain = 16 Participants

Cabergoline as a preventive migraine treatment: A randomized clinical pilot trial

Not Applicable; n=36; evaluation: Positive. Reported fields: MMD = 14.0 days ( 5.3); MMD = 13.6 days ( 4.1)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cabergoline addresses Lactation Disorders, Parkinson Disease, Hyperprolactinemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 85 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: D2 receptor records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-23	HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties	Approved	Financial terms not disclosed
2026-04-21	Tortugas Neuroscience licensed TRTL-107 and TRTL-913 from China’s Hansoh	Phase 2	Financial terms not disclosed
2026-04-15	上药控股携手强生达成CNS领域战略合作	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Computational repurposing of the cabergoline as novel”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO